TP53 and cancer: Interrogating all 1074 individuals with FGF/FGFR-altered tumors, those harboring alterations in both FGF/FGFR and in the TP53 pathway (HR: 0.61, 95% CI 0.48-0.79, P = 0.0001; Figure 3A) or in the cell cycle pathway (along with the FGF/FGFR genes) (HR: 0.74, 95% CI 0.59-0.92, P = 0.0065; Figure 3B) had significantly shorter OS when compared to patients with FGF/FGFR-altered cancers without those co-altered anomalies.